www.fdanews.com/articles/197765-sanofi-reports-faster-progress-for-covid-19-vaccine-candidate
![Sanofi-logo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images/Sanofi-logo.gif?t=1604968321&width=430)
Sanofi Reports Faster Progress for COVID-19 Vaccine Candidate
June 24, 2020
Swiss drugmaker Sanofi said it has progressed faster than anticipated with a COVID-19 vaccine candidate being developed in collaboration with GlaxoSmithKline (GSK).
Sanofi CEO Paul Hudson said the recombinant DNA vaccine, which is using GSK’s adjuvant, is now expected to enter a phase 1/2 study in September and could receive full approval by the first half of next year.
Hudson said Sanofi currently has the manufacturing capacity to produce up to 1 billion annual doses of the recombinant vaccine and 90 million to 360 million annual doses of a messenger RNA vaccine it is developing with Massachusetts-based Translate Bio.